Article
Targeting CD137 enhances the efficacy of cetuximab.
The Journal of clinical investigation - 1 Jun 2014
Kohrt Holbrook E, Colevas A Dimitrios, Houot Roch, Weiskopf Kipp, Goldstein Matthew J, Lund Peder, Mueller Antonia, Sagiv-Barfi Idit, Marabelle Aurelien, Lira Ruth, Troutner Emily, Richards Lori, Rajapaska Amanda, Hebb Jonathan, Chester Cariad, Waller Erin, Ostashko Anton, Weng Wen-Kai, Chen Lieping, Czerwinski Debra, Fu Yang-Xin, Sunwoo John, Levy Ronald
Abstract excerpt
Treatment with cetuximab, an EGFR-targeting IgG1 mAb, results in beneficial, yet limited, clinical improvement for patients with head and neck (HN) cancer as well as colorectal cancer (CRC) patients with WT KRAS tumors. Antibody-dependent cell-mediated cytotoxicity (ADCC) by NK cells contributes to the efficacy of cetuximab. The costimulatory molecule CD137 (4-1BB) is expressed following NK and memory T cell...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.